secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001564590-21-041591
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences reports Q2 net loss of $76M, cash $805M; appoints Nicole Lambert to board
--------------------------------------------------------------------------------

- Net loss $76.0M for Q2 2021 vs $45.1M in Q2 2020; six-month net loss $148.6M.
- Collaboration revenue $9.5M in Q2 2021 vs $1.8M; R&D expenses $68.8M (up from $35.7M).
- Cash and investments $805.1M as of June 30, 2021 vs $735.1M at Dec 31, 2020; funded at least through 2023.
- Appointed Nicole Lambert to Board of Directors, President of Myriad Genetic Laboratories.
- Pipeline: HIF-2α inhibitor AB521 enters clinic in Q4 2021; domvanalimab combination data promising; randomized ARC-8 enrollment to complete by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000156459021041591/0001564590-21-041591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000156459021041591/rcus-8k_20210803.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-041591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer